Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-11-17
1999-03-09
Ramsuer, Robert W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
5462741, A61K 3144, C07D40104
Patent
active
058801391
ABSTRACT:
2,4-Diaryl-5-pyridylimidazoles are glucagon antagonists. The compounds block the action of glucagon at its receptor. Thus, the compounds can be used in the prophylaxis or treatment of disease states in mammals mediated by elevated levels of glucagon. Examples of such disease states include diabetes, obesity, hypertension, and cachexia and the like.
REFERENCES:
patent: 3772441 (1973-11-01), Lombardino
patent: 3929807 (1975-12-01), Fitzi
patent: 5620999 (1997-04-01), Weier et al.
patent: 5686455 (1997-11-01), Adams et al.
Merck & Co. , Inc.
Ramsuer Robert W.
Rose David L.
Yang Mollie M.
LandOfFree
Triaryl substituted imidazoles as glucagon antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triaryl substituted imidazoles as glucagon antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triaryl substituted imidazoles as glucagon antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1321438